The U.S. Food and Drug Administration (FDA) revised the boxed warning on the label for Liraglutide (Xultophy 100/3.6, Saxenda, Victoza, insulin degludec and liraglutide) effective 2026-07-27. This revision highlights the risk of thyroid C-cell tumors associated with the drug.
Background
The revised boxed warning for Liraglutide, effective 2026-07-27, specifically addresses the RISK OF THYROID C-CELL TUMORS. The warning states that Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. It also notes that it is unknown whether Liraglutide causes thyr.
What this means
The updated boxed warning for Liraglutide carries significant implications for prescribing practices and patient counseling. Healthcare providers must now give even greater consideration to the potential risk of thyroid C-cell tumors, especially given the observed dose-dependent and treatment-duration-dependent effects in animal studies. This necessitates thorough patient evaluation prior to initiating treatment, careful risk-benefit assessment, and vigilant monitoring for any signs or symptoms related to thyroid C-cell abnormalities throughout the course of therapy. For patients and patient advocates, this revision underscores the importance of understanding these potential risks. It highlights the need to engage in detailed discussions with their healthcare team about the most appropriate treatment options, potential alternatives, and safety precautions, particularly concerning their thyroid health and any family history of thyroid conditions. Shared decision-making between patients and clinicians becomes even more critical with this updated safety information.
Source
This information was sourced from the FDA, detailing a label revision for Liraglutide effective 2026-07-27. The full details of the revised label are available on dailymed.nlm.nih.gov.